

PRESS RELEASE

ProBioGen Is Granted Divisional Patent on Its Proprietary AGE1 Cell Line

Berlin, April 1st, 2010 - ProBioGen AG, a leading biotechnology company in cell engineering and production of biopharmaceuticals, today announced that it has been granted a divisional patent on its AGE1 cell line.

The patent covers the production of Modified Vaccinia Ankara (MVA) in duck cell lines. As these cells are free from endogenous particle-associated retrovirus activity, they are superior to current production substrates derived from chicken. The discovery has wide implications for the industrial production of one of the most promising recombinant vaccine vectors against infectious disease challenges such as HIV and malaria.

“The granted divisional patent further strengthens ProBioGen's proprietary platform that extends from innovative host cell lines to chemically defined production processes for highly attenuated viruses,” said Dr. Volker Sandig, Chief Scientific Officer of ProBioGen. An additional application on AGE1 with yet broader implications has been filed.

###

About ProBioGen AG

ProBioGen is a leading cell specialist. By combining deep molecular understanding of cells with state-of-the-art industry process engineering and production know-how, ProBioGen's technologies enable biopharmaceutical companies to develop products with superior efficiency, safety and a more favourable cost profile. Since its inception in 1994, the company has processed more than 300 cell lines and established a GMP unit based on disposable reactor technology, which supports all currently available manufacturing processes. The company is headquartered in Berlin.

About AGE1.CR

AGE1.CR has been developed by ProBioGen in cooperation with IDT Biologika GmbH to replace embryonated chicken eggs and chicken embryonic fibroblasts as substrate for production of human and animal vaccines. The immortal cell line obviates dependence on external supply of pharmaceutical grade calf serum and SPF chicken and thus allows production of therapeutics and vaccines in closed systems. AGE1.CR is derived from specific tissue of a single duck embryo without feeder cell layers. This cell line fully supports the production of a wide spectrum of wild-type and recombinant viruses, including highly attenuated poxviruses. In the AGE1.CR cell line from muscovy duck no particle-associated retrovirus activity has been detected. The approach in generating the cell line is consistent with the “defined risk” guidelines issued by the FDA. Exhaustive analytical tests required for regulatory submission with US and European regulatory agencies have been

performed. The resulting data package provides a strong background for application of AGE1.CR as a producer cell line for biopharmaceuticals.

Contact for ProBioGen:

Dr Gertraud Unterrainer, CFO
Goethestrasse 54
13086 Berlin
Tel.: +49 (0)30 924 006-0
Fax: +49 (0)30 924 006-19
email: info@probiogen.de